Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Unravelling mutational signatures with plasma circulating tumour DNA.

Nature communications - 14 Nov 2024

Hollizeck Sebastian, Wang Ning, Wong Stephen Q, Litchfield Cassandra, Guinto Jerick, Ftouni Sarah, Rebello Richard, Kanwal Sehrish, Dong Ruining, Grimmond Sean, Sandhu Shahneen, Mileshkin Linda, Tothill Richard W, Chandrananda Dineika, Dawson Sarah-Jane

Abstract excerpt

The use of circulating tumour DNA (ctDNA) to profile mutational signatures represents a non-invasive opportunity for understanding cancer mutational processes. Here we present MisMatchFinder, a liquid biopsy approach for mutational signature detection using low-coverage whole-genome sequencing of ctDNA. Through analysis of 375 plasma samples across 9 cancers, we demonstrate that MisMatchFinder accurately infers...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Circulating Tumor DNA

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Mutational Analysis

Share to DNA, Neoplasm

Share to Liquid Biopsy

Share to Mutation

Share to Neoplasms

Share to Whole Genome Sequencing

Source

Open in PubMed Open full text

Identifiers

PMID: 39543119
DOI: 10.1038/s41467-024-54193-2
PMCID: PMC11564803

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Unravelling mutational signatures with plasma circulating tumour DNA.PMID 39543119Read ↗

Noninvasive MRD monitoring and profiling of clonal evolution by ctDNA in patients with advanced cancers treated within molecular tumor boardsSemantic proximity Read ↗

Genetic profiling of cancer with circulating tumor DNA analysis.Semantic proximity Read ↗

Extending Circulating Tumor DNA Analysis to Ultralow Abundance Mutations: Techniques and Challenges.Semantic proximity Read ↗

Utilizing Plasma Circulating Tumor DNA Sequencing for Precision Medicine in the Management of Solid Cancers.Semantic proximity Read ↗

Assessing the Concordance of Genomic Alterations between Circulating-Free DNA and Tumour Tissue in Cancer PatientsSemantic proximity Read ↗

Combining mutation detection with fragmentomics features leads to improved tumor-informed ctDNA detectionSemantic proximity Read ↗

Detection of Circulating Tumor DNA in Plasma Using Targeted Sequencing.Semantic proximity Read ↗

Whole genome error-corrected sequencing for sensitive circulating tumor DNA cancer monitoringSemantic proximity Read ↗

Genomic Landscape of Advanced Solid Tumors in Circulating Tumor DNA and Correlation With Tissue Sequencing: A Single Institution's ExperienceSemantic proximity Read ↗

Liquid biopsies across the cancer care continuum.Semantic proximity Read ↗

Clinical relevance of blood-based ctDNA analysis: mutation detection and beyondSemantic proximity Read ↗

Leveraging the Fragment Length of Circulating Tumour DNA to Improve Molecular Profiling of Solid Tumour Malignancies with Next-Generation Sequencing: A Pathway to Advanced Non-invasive Diagnostics in Precision Oncology?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.